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Epigenetic alterations consisting mainly of DNA methylation alterations and histone modiﬁ-
cation alterations are frequently observed in cancers associated with chronic inﬂammation
and/or persistent infection with viruses or other pathogenic microorganisms, or with
cigarette smoking. Accumulating evidence suggests that alterations of DNA methylation
are involved even in the early and precancerous stages. On the other hand, in patients with
cancers, aberrant DNAmethylation is frequently associatedwith tumor aggressiveness and
poor patient outcome. Recently, epigenome alterations have been attracting a great deal of
attention from researcherswho are focusing on not only cancers but also neuronal, immune
andmetabolic disorders. In order to accurately identify disease-speciﬁc epigenome proﬁles
that could be potentially applicable for disease prevention, diagnosis and therapy, strict
comparisonwith standard epigenome proﬁles of normal tissues is indispensable. However,
epigenome mechanisms show heterogeneity among tissues and cell lineages. Therefore,
it is not easy to obtain a comprehensive picture of standard epigenome proﬁles of normal
tissues. In 2010, the International Human Epigenome Consortium (IHEC) was established
to coordinate the production of reference maps of human epigenomes for key cellular
states. In order to gain substantial coverage of the human epigenome, the IHEC has
set an ambitious goal to decipher at least 1000 epigenomes within the next 7–10 years.
We consider that pathway analysis using genes showing multilayer-omics abnormalities,
including genome, epigenome, transcriptome, proteome and metabolome abnormalities,
may be useful for elucidating the molecular background of pathogenesis and for exploring
possible therapeutic targets for each disease.
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MICRO RNAs AND HUMAN DISEASES
The Encyclopedia of DNA Elements (ENCODE) Consortium1
data have revealed in more detail the high degree of complexity
of the mammalian transcriptome: 75% of the genome is tran-
scribed intodifferent types of RNAmolecules, e.g., protein-coding,
long non-coding, pseudogenes, and small RNA genes (Djebali
et al., 2012). RNA molecules show much greater variety than
previously suspected. Among such RNA molecules, microRNAs
(miRNAs) are non-coding RNAs comprising about 22 nucleotides
initially transcribed by RNA polymerase II as primary miRNA
(pri-miRNA) molecule precursors that possess a stem loop struc-
ture (Jinek and Doudna, 2009). RNase III Drosha acts over
Abbreviations: CIMP, CpG island methylator phenotype; COPD, chronic obstruc-
tive pulmonary disease; IHEC, International Human Epigenome Consortium; LC,
normal lung tissue; LN, non-cancerous lung tissue obtained from patients with lung
adenocarcinoma; LT, lung adenocarcinoma tissue; PBAT, post-bisulﬁte adaptor-
tagging; RC, normal renal cortex tissue; RN, non-cancerous renal cortex tissue
obtained from patients with clear cell renal cell carcinoma; RT, clear cell renal cell
carcinoma tissue.
1https://genome.ucsc.edu/ENCODE/
pri-mRNAs generating a pre-miRNAcontaining the hairpin (Jinek
and Doudna, 2009). The pre-miRNAs are then exported to the
cytoplasm and processed by Dicer into mature miRNAs, which are
subsequently translocated into the RNA-induced silencing com-
plex (RISC; Gomes et al., 2013). Each miRNA has multiple tasks,
such as transcriptional repression via binding to partially com-
plementary sequences in the 3′-untranslated regions of the target
mRNAs and direct mRNA degradation via binding to perfectly
complementary sequences (He and Hannon, 2004). Therefore,
deregulation of miRNA levels may disturb the expression pro-
ﬁles in cells, thereby playing a key role in induction of diseases,
such as cancers, neurodegenerative diseases, and autoimmune
diseases.
EPIGENETICS AND miRNAs
Saito et al. revealed that treatment with the DNA demethylating
agent 5-aza-2′-deoxycytidine and the histone deacetylase inhibitor
4-phenylbutyric acid induced marked changes in the expression
proﬁles of miRNAs in human cancer cell lines. In particular, DNA
hypermethylation and induction of active histone marks in the
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promoter region of miR-127 resulted in decreased and increased
expression of miR-127, respectively (Saito et al., 2006). Activa-
tion of miR-512-5p by epigenetic treatment induced apoptosis of
human gastric cancer cell lines via suppression of the MCL1 gene
(Saito et al., 2009). In the human colon cancer cell line HCT116,
disturbance of miRNA expression patterns has been reported
after disruption of both DNA methyltransferase (DNMT) 1 and
DNMT3B (Lujambio et al., 2007). Findings accumulated to date
clearly indicate that expression levels of multiple miRNAs, such as
let-7a-3, miR-1, miR-9-1, miR-9-3, miR-34a, mir34a*, mir34b/c,
miR-124a, miR-126. miR127, miR-342, and miR-512-5p, are
regulated epigenetically (Saito et al., 2013).
On the other hand, the expression of many proteins involved in
epigenetics is regulated bymiRNAs. For example,miR-152 acts as a
tumor suppressor via suppression of DNMT1 (Huang et al., 2010).
The miR-29 family targetsDNMT3A andDNMT3B, whereas miR-
101 targetsEZH2 andmay alter global chromatin structure (Fabbri
et al., 2007). In addition, it has been shown that miRNA has the
capacity to recognize chromatin by increasing the methylation of
histone, for example through histone H3 lysine 27 tri-methylation
(Kim et al., 2008). Thus the close connection between epigenetic
alterations and miRNA dysregulation may have a great impact on
human diseases.
PARTICIPATION OF EPIGENETIC ALTERATIONS IN
MULTISTAGE HUMAN CARCINOGENESIS
Epigenetic alterations, consisting mainly of DNA methyla-
tion alterations and histone modiﬁcation alterations, are often
observed in cancers that are associated with chronic inﬂammation
and/or persistent infection with viruses, such as hepatitis B or C
viruses, Epstein–Barr virus, and human papillomavirus, or with
cigarette smoking (Kanai andHirohashi, 2007). Accumulating evi-
dence suggests that alterations of DNA methylation are involved
even in the early and precancerous stages (Arai and Kanai, 2010).
On the other hand, in patients with cancers, aberrant DNA methy-
lation is frequently associated with tumor aggressiveness and poor
patient outcome (Kanai, 2008). Precancerous conditions showing
alterations of DNA methylation may progress rapidly and generate
more malignant cancers (Kanai, 2010).
Aswe described in thewebpage of our laboratory2, even though
genetic alterations, such as activation of oncogenes and inactiva-
tion of tumor suppressor genes, have been considered to provide
the molecular framework of multistage human carcinogenesis,
genetic events alone may not explain the histological heterogene-
ity underlying the complex biological characteristics of tumors.
Therefore, in the 1990s, we began to focus on epigenetic events that
can be reversible, in an attempt to explain why cancers show such
histopathological heterogeneity. At a timewhenonly two genes,RB
andVHL, were known as tumor suppressor genes silenced by DNA
methylation, we showed for the ﬁrst time that the CDH1 gene,
which encodes the E-cadherin cell adhesion molecule and acts
as tumor suppressor, is silenced by DNA methylation around the
promoter region in human cancers (Yoshiura et al., 1995). In 1996,
we demonstrated that DNA methylation alterations frequently
occurred at multiple loci on chromosome 16, one of the hot spots
2http://www.ncc.go.jp/en/nccri/divisions/01path/01path01.html
for loss of heterozygosity in liver cancers. This preceded loss of het-
erozygosity even at the chronic hepatitis or liver cirrhosis stages,
which are widely considered to be precancerous conditions. This
was one of the earliest reports of aberrant DNA methylation at the
precancerous stage (Kanai et al., 1996).
Since then, we have reported DNA methylation alterations
in tissue specimens at precancerous stages and in cancers using
a candidate-gene approach. As an example of inﬂammation-
associated carcinogenesis, ductal adenocarcinomas of the pancreas
frequently develop in a background of chronic pancreatitis. Under
these conditions, at least a proportion of peripheral pancreatic
duct epithelia may be at the precancerous stage. It has been
reported that the average number of methylated tumor-related
genes, the incidence of DNA methylation of at least one of such
genes, and the expression level of DNMT1 protein are increased in
pancreatic duct epithelia with an inﬂammatory background, and
in another precancerous lesion, pancreatic intraductal neoplasia
(PanIN), in comparison with normal pancreatic duct epithelia
(Peng et al., 2006).
Urothelial carcinomas of the urinary bladder, renal pelvis, and
ureter are clinically remarkable because of their multicentricity
and tendency to recur. Such multiplicity may be attributable
to the “ﬁeld effect.” Even non-cancerous urothelia showing no
marked histological ﬁndings from patients with urothelial car-
cinomas can be considered precancerous, because they may have
been exposed to carcinogens in the urine. It has been reported that
the average number of methylated tumor-related genes and the
expression level of DNMT1protein are increased innon-cancerous
urothelia showing no marked histological ﬁndings from patients
with urothelial carcinomas, in comparison with normal urothe-
lia from patients without urothelial carcinomas (Nakagawa et al.,
2005). Thus, overexpression of the major DNMT, DNMT1, may
result in accumulated hypermethylation of DNA for tumor-related
genes (Etoh et al., 2004). On the other hand, splicing alteration
of DNMT3B may induce chromosomal instability through DNA
hypomethylation of pericentromeric satellite regions (Saito et al.,
2002).
As we described in the webpage of our laboratory2, after
genome-wide epigenetic (epigenome) analysis had become practi-
cal, we employed the bacterial artiﬁcial chromosome array-based
methylated CpG island ampliﬁcation (BAMCA) method for
overviewing the DNA methylation tendency of large individual
chromosomal regions. Although precancerous conditions in the
kidney have rarely been described, despite the lack of any marked
histological ﬁndings or association with chronic inﬂammation or
persistent infection with pathogens, it can be considered that non-
cancerous renal cortex tissue obtained from patients with renal
cancers is already at the precancerous stage showing genome-wide
DNA methylation alterations (Arai et al., 2006). We showed that
DNA methylation proﬁles at the precancerous stage are inher-
ited by renal cancers developing in individual patients, and that
DNA methylation alterations at the precancerous stage determine
both the aggressiveness of subsequently developing cancers and
patient outcome through inducing further epigenetic and genetic
alterations (Arai et al., 2009a). In addition, we have developed
indicators for carcinogenetic risk estimation in patients with
chronic hepatitis and liver cirrhosis (Arai et al., 2009b), indicators
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for estimating the risk of development of urothelial carcinomas
that can be determined from urine samples (Nishiyama et al.,
2010), diagnosticmarkers of pancreatic cancer that can be assessed
from specimens of pancreatic juice (Gotoh et al., 2011), and indi-
cators for prognostication of kidney, liver, pancreas, and urinary
bladder cancers based on DNA methylation proﬁling. Based on
these ﬁndings, we have ﬁled patent applications for epigenome
diagnosis techniques, and are now attempting to apply them
practically.
ACTIVITIES OF THE INTERNATIONAL HUMAN EPIGENOME
CONSORTIUM (IHEC)
Recently, epigenome alterations have been attracting a great deal
of attention from researchers who are focusing on not only cancers
but also neuronal, immune, and metabolic disorders. On the basis
of epigenome proﬁling, attempts are now being made to elucidate
the molecular pathogenesis of such diseases and to explore pos-
sible biomarkers and drug targets. In order to accurately identify
such disease-speciﬁc epigenome proﬁles that could be potentially
applicable for disease prevention, diagnosis, and therapy, strict
comparison with standard epigenome proﬁles of normal tissues
is indispensable. However, epigenome mechanisms show hetero-
geneity among tissues and cell lineages. Therefore, it is not easy
to obtain a comprehensive picture of standard epigenome pro-
ﬁles of normal tissues. Based on improvements in next-generation
sequencing technology, international collaboration will likely help
to reveal standard epigenome proﬁles.
In 2010, the IHEC was established by researchers and founding
agencies from Canada, South Korea, the EU, Italy, Germany, Japan,
and the USA (Bae, 2013). As described in the webpage of IHEC3,
the primary goal of the IHEC is “to coordinate the production of
reference maps of human epigenomes for key cellular states that
are relevant to health and diseases.” In order to achieve substantial
coverage of the human epigenome, the IHEC has set an ambitious
goal to decipher at least 1000 epigenomes3. To attain this goal,
IHEC will use robust techniques to generate (1) high-resolution
maps of histonemodiﬁcations,H3K4me3,H3K9me3,H3K27me3,
H3K27ac, H3K4me1, and H3K36me3, (2) high-resolution DNA
methylation maps, (3) landmark maps of transcription start sites
for all protein-encoding genes, and (4) a comprehensive catalog
of non-coding and small RNAs and their patterns of expression3.
The target cell types being studied by each team in the participating
countries are shown on the IHEC website4.
In Japan, three Japanese IHEC teams5 including our team
are supported by the Core Research for Evolutional Science
and Technology division of the Japan Science and Technology
Agency. To strengthen the research bases for cancers of digestive
organs, including hepatocellular carcinomas and gastric carcino-
mas, which show high incidences in Japan, we are now performing
standard epigenome analyses of normal epithelial cell lineages
in digestive organs (Figure 1). Target cells of sufﬁcient quality
and quantity are being obtained from materials surgically resected
from a range of Japanese patients. For example, for liver, we have
3http://ihec-epigenomes.org/about/objectives/
4http://ihec-epigenomes.org/research/cell-types/
5http://crest-ihec.jp/
obtained samples of normal liver tissue distant from sites of liver
metastases from primary colon cancers in partial hepatectomy
specimens from patients without viral hepatitis, chronic hepati-
tis, or liver cirrhosis. To isolate hepatocytes, we have performed
collagenase perfusion of cannulated branches of the hepatic vein,
followed by low-velocity centrifugation. On average, more than
107 dispersed cells can be obtained from each case, and immuno-
cytochemistry has conﬁrmed that the hepatocytes are more than
95% pure. In the stomach and colorectum, we initially employ the
crypt isolation technique and collagenase digestion. Thereafter,
each normal cell lineage is puriﬁed by ﬂuorescence activated cell
sorting using appropriate antibodies.
Members of our IHEC teamhave originally developed the post-
bisulﬁte adaptor-tagging method (PBAT), which is an efﬁcient
library preparation method for whole-genome bisulﬁte sequenc-
ing (Miura et al., 2012). For the PBAT method, we ﬁrst perform
bisulﬁte modiﬁcation followed by adaptor ligation using random
priming. The PBAT method minimally requires sub-microgram
DNA for mammalian whole-genome bisulﬁte sequencing without
global PCRampliﬁcation. A good correlation of theDNAmethyla-
tion patternwas observed amongPBAT, the standardMethyl C-seq
methodology developed by Lister et al. (2008), and the Illumina
beads chip Inﬁnium assay. The PBAT method is advantageous in
that it requires only a small amount of genomic DNA but has good
coverage of GC-rich regions, especially in CpG islands and gene-
rich chromosomes. We now propose to make the PBAT method
one of the standard protocols for IHEC. Under the supervision
of the IHEC, we intend to disclose the data we obtain through
the National Bioscience Database Center supported by the Japan
Science and Technology Agency. Accurate standard epigenome
proﬁles of digestive organ epithelial cells obtained through IHEC
activities will be used to explore more useful biomarkers and drug
targets of digestive organ cancers.
MULTILAYER/INTEGRATIVE DISEASE OMICS ANALYSES FOR
EXPLORATION OF BIOMARKERS AND DRUG TARGETS
Recently big data analysis has impacted various ﬁelds of bio-
science, especially disease research. It may not be appropriate to
perform epigenome analysis including miRNA analysis using clin-
ical samples. Instead, simultaneous multilayer/integrative disease
omics analyses would seem more appropriate, including genome,
epigenome, transcriptome, proteome, and metabolome analy-
ses for exploration of drug targets. Since 2010, researchers at
six National Centers in Japan, i.e., the National Cancer Center,
National Cerebral and Cardiovascular Center, National Center
for Neurology and Psychiatry, National Center for Global Health
and Medicine, National Center for Child Health and Develop-
ment and National Center for Geriatrics and Gerontology, have
been engaged in a research project “Comprehensive exploration
of drug targets based on multilayer/integrative disease omics anal-
yses” supported by the Program for Promotion of Fundamental
Studies in Health Sciences of the National Institute of Biomedi-
cal Innovation (NiBio) (Figure 2). This project has been divided
among a number of centers specializing in genome, epigenome,
transcriptome, proteome, and metabolome analyses of tissue
specimens from patients with various diseases that show a high
incidence in the Japanese population. Tissue and body ﬂuid
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FIGURE 1 | Activity of our team, one of the JapanTeams of the Inter-
national Human Epigenome Consortium supported by the Core Research
for Evolutional Science andTechnology division of the Japan Science
andTechnology Agency (modified from the webpage of our laboratory
[http://www.ncc.go.jp/en/nccri/divisions/01path/01path01.html]). We
are now performing whole-genome bisulﬁte sequencing using the
post-bisulﬁte adaptor-tagging method, chromatin
immunoprecipitation-sequencing, and RNA-sequencing of puriﬁed target
cells, i.e., hepatocytes and other live cell lineages, foveolar epithelial cells,
and other gastric epithelial cell lineages, and absorptive epithelial cells from
the ascending and descending colon and rectum. Accurate epigenome
proﬁling of normal cells will allow the identiﬁcation of disease-speciﬁc
epigenome proﬁles, thus facilitating a potential breakthrough in the
prevention, diagnosis, and therapy of diseases.
specimens, cultured cells and animal models of adult cancers,
infant leukemia, allergic disease, dilated cardiomyopathy, aortic
aneurysm, epilepsy, obesity, non-alcoholic steatohepatitis, spinal
canal stenosis, and Alzheimer’s disease have been subjected to
multilayer-omics analyses. As we described in the webpage of our
laboratory2, we are especially focusing on molecules or molecular
pathways which are impaired as a result of multiple mechanisms,
such as events in all ﬁve omics layers, which may participate in the
molecular pathogeneses of diseases and might become potential
biomarkers and/or druggable targets (Figure 2).
With regard to epigenome analysis of adult cancers in this
research project, 414 lung tissue specimens including normal lung
tissue (LC) obtained from patients without any primary lung
tumor, non-cancerous lung tissue (LN) obtained from patients
with lung adenocarcinomas, and lung adenocarcinoma tissue (LT)
itself have been subjected to single-CpG resolution Inﬁnium assay.
DNA methylation alterations on many probes were evident in LN
samples relative to LC samples, and were inherited by, or strength-
ened in, LT samples. Unsupervised hierarchical clustering using
DNA methylation levels in LN samples subclustered patients into
clusters I, II, and III. Lung adenocarcinomas in cluster I devel-
oped from an inﬂammatory background in chronic obstructive
pulmonary disease (COPD) in heavy smokers, and were locally
invasive. Most patients in cluster II were non-smokers and had
a favorable outcome. Lung adenocarcinomas in cluster III were
most aggressive cancers in light smokers that developed before
accumulation of the long-term effects of cigarette smoking, and
were probably due to the direct actions of carcinogens, rather than
the effects of inﬂammation. DNA methylation proﬁles reﬂecting
carcinogenetic factors such as smoking and COPD appear to be
established inLNs andmaydetermine the aggressiveness of tumors
developing in individual patients, and thus patient outcome (Sato
et al., 2014). Among the genes for which DNA methylation sta-
tus in LN samples was signiﬁcantly correlated with recurrence
of lung adenocarcinomas in individual patients, we focused on
ADCY5, EVX1, and other genes that were involved in apoptosis
and cell adhesion. The mRNA expression levels of these genes
were directly regulated by DNA methylation, and a decrease of
their mRNA expression in LT samples was signiﬁcantly correlated
with tumor aggressiveness (Sato et al., 2013). When these genes
were ectopically expressed in lung cancer cell lines, growth sup-
pression, and apoptosis were induced, indicating that these genes
could become therapeutic targets of lung adenocarcinomas.
With regard to epigenome analysis during renal carcinogen-
esis, 245 renal tissue specimens including normal renal cortex
tissue (RC) obtained from patients without any primary renal
cancer, non-cancerous renal cortex tissue (RN) obtained from
patients with clear cell renal cell carcinomas, and clear cell
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FIGURE 2 | Brief overview of the “Comprehensive exploration of drug
targets based on multilayer/integrative disease omics analyses” project
supported by the Program for Promotion of Fundamental Studies in
Health Sciences of the National Institute of Biomedical Innovation
(modified from the webpage of our laboratory [http://www.ncc.go.jp/
en/nccri/divisions/01path/01path01.html]). In this project, researchers in
several National Centers in Japan have been split up into analytical centers for
genome, epigenome, transcriptome, proteome, and metabolome.We have
been focusing on molecules or molecular pathways that are impaired by
multiple mechanisms, such as genome and epigenome events, or events in
all ﬁve omics layers, which may participate in the molecular pathogeneses of
those diseases and might become drug targets.
renal cell carcinoma tissue (RT) itself were subjected to the
Inﬁnium assay. DNA methylation levels at multiple Inﬁnium
probe sites were already altered in RN samples relative to RC
samples. Unsupervised hierarchical clustering analysis based on
DNA methylation levels at the CpG sites where DNA methy-
lation alterations had occurred even in RN samples and were
inherited by, and strengthened in, RT samples divided the clear
cell renal cell carcinomas into CpG island methylator pheno-
type (CIMP)-positive and -negative clusters (Arai et al., 2012).
Clinicopathologically aggressive cancers were accumulated in the
CIMP-positive cluster, where the cancer-free and overall survival
rates of the patients were signiﬁcantly lower than in the CIMP-
negative cluster. FAM150A, GRM6, ZNF540, ZFP42, ZNF154,
RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC, WNT3A,
TRH, FAM78A, ZNF671, SLC13A5, and NKX6-2 have been identi-
ﬁed as renal cell carcinoma-speciﬁcCIMPmarker genes (Arai et al.,
2012). Since CIMP-positive renal cell carcinomas show tumor
aggressiveness and poorer patient outcome, we established criteria
for prognostication of patients with clear cell renal cell carcino-
mas using renal cell carcinoma-speciﬁc CIMP marker genes. We
are now performing pathway analysis based on a Bayesian esti-
mation model using multiple genes showing frequent mutations
and alterations of expression at the mRNA, miRNA, and protein
levels based on multilayer-omics analyses in each of the CIMP-
negative and CIMP-positive renal cell carcinomas for exploration
of possible drug targets.
PERSPECTIVES
Once DNA methylation alterations occur during multistage
carcinogenesis, such alterations are stably preserved on DNA
double strands through maintenance methylation mechanisms
by DNMT1. Therefore, stable stratiﬁcation of cancers reﬂect-
ing clinicopathological diversity may be possible based on
epigenome proﬁling. Genes showing epigenome alterations,
such as CIMP-marker genes, may become excellent biomark-
ers discriminating each tumor type stratiﬁed on the basis
of epigenome proﬁling. We consider that pathway analy-
sis using genes showing multilayer-omics abnormalities after
stratiﬁcation based on epigenome proﬁling may be useful for elu-
cidating the molecular background of carcinogenetic pathways
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and for exploring possible therapeutic targets for each tumor
type.
ACKNOWLEDGMENTS
This study was supported by the Core Research for Evolutional
Science and Technology (CREST) division “Development of Fun-
damental Technologies for Diagnosis and Therapy Based upon
Epigenome Analysis” of the Japan Science and Technology Agency
(JST), the Program for Promotion of Fundamental Studies in
Health Sciences from the NiBio, a Grant in Aid for the Third
Term Comprehensive 10-Year Strategy for Cancer Control from
the Ministry of Health, Labor and Welfare of Japan, and Grants in
Aid for Scientiﬁc Research (B) and (C) from the Japan Society for
the Promotion of Science (JSPS). Tissue specimens were provided
by the National Cancer Center Biobank, which is supported by the
National Cancer Center Research and Development Fund, Japan.
REFERENCES
Arai, E., Chiku, S., Mori, T., Gotoh, M., Nakagawa, T., Fujimoto, H., et al.
(2012). Single-CpG-resolution methylome analysis identiﬁes clinicopathologi-
cally aggressive CpG island methylator phenotype clear cell renal cell carcinomas.
Carcinogenesis 33, 1487–1493. doi: 10.1093/carcin/bgs177
Arai, E., and Kanai, Y. (2010). DNA methylation proﬁles in precancerous tissue
and cancers: carcinogenetic risk estimation and prognostication based on DNA
methylation status. Epigenomics 2, 467–481. doi: 10.2217/epi.10.16
Arai, E., Kanai, Y., Ushijima, S., Fujimoto, H., Mukai, K., and Hirohashi, S. (2006).
Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 pro-
tein overexpression in both renal tumors and corresponding nontumorous renal
tissues. Int. J. Cancer 119, 288–296. doi:10.1002/ijc.21807
Arai, E., Ushijima, S., Fujimoto, H., Hosoda, F., Shibata, T., Kondo, T., et al. (2009a).
Genome-wide DNA methylation proﬁles in both precancerous conditions and
clear cell renal cell carcinomas are correlated with malignant potential and patient
outcome. Carcinogenesis 30, 214–221. doi: 10.1093/carcin/bgn268
Arai, E., Ushijima, S., Gotoh, M., Ojima, H., Kosuge, T., Hosoda, F., et al.
(2009b). Genome-wide DNA methylation proﬁles in liver tissue at the precan-
cerous stage and in hepatocellular carcinoma. Int. J. Cancer 125, 2854–2862. doi:
10.1002/ijc.24708
Bae, J. B. (2013). Perspectives of international human epigenome consortium.
Genomics Inform. 11, 7–14. doi: 10.5808/GI.2013.11.1.7
Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., et al.
(2012). Landscape of transcription in human cells. Nature 489, 101–108. doi:
10.1038/nature11233
Etoh, T., Kanai,Y., Ushijima, S., Nakagawa, T.,Nakanishi,Y., Sasako,M., et al. (2004).
Increased DNA methyltransferase 1 (DNMT1) protein expression correlates sig-
niﬁcantly with poorer tumor differentiation and frequentDNAhypermethylation
of multiple CpG islands in gastric cancers. Am. J. Pathol. 164, 689–699. doi:
10.1016/S0002-9440(10)63156-2
Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., et al. (2007).
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting
DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A. 104, 15805–
15810. doi:10.1073/pnas.0707628104
Gomes, A. Q., Nolasco, S., and Soares, H. (2013). Non-coding RNAs: multi-
tasking molecules in the cell. Int. J. Mol. Sci. 14, 16010–16039. doi:
10.3390/ijms140816010
Gotoh, M., Arai, E., Wakai-Ushijima, S., Hiraoka, N., Kosuge, T., Hosoda, F.,
et al. (2011). Diagnosis and prognostication of ductal adenocarcinomas of the
pancreas based on genome-wide DNA methylation proﬁling by bacterial artiﬁ-
cial chromosome array-based methylated CpG island ampliﬁcation. J. Biomed.
Biotechnol. 2011, 780836. doi: 10.1155/2011/780836
He, L., and Hannon, G. J. (2004). MicroRNAs: small RNAs with a big role in gene
regulation. Nat. Rev. Genet. 5, 522–531. doi: 10.1038/nrg1379
Huang, J., Wang, Y., Guo, Y., and Sun, S. (2010). Down-regulated microRNA-152
induces aberrant DNA methylation in hepatitis B virus-related hepatocellular
carcinoma by targeting DNA methyltransferase 1. Hepatology 52, 60–70. doi:
10.1002/hep.23660
Jinek, M., and Doudna, J. A. (2009). A three-dimensional view of the molec-
ular machinery of RNA interference. Nature 457, 405–412. doi: 10.1038/
nature07755
Kanai, Y. (2008). Alterations of DNA methylation and clinicopathological
diversity of human cancers. Pathol. Int. 58, 544–558. doi: 10.1111/j.1440-
1827.2008.02270.x
Kanai, Y. (2010). Genome-wide DNA methylation proﬁles in precancerous con-
ditions and cancers. Cancer Sci. 101, 36–45. doi: 10.1111/j.1349-7006.2009.
01383.x
Kanai, Y., and Hirohashi, S. (2007). Alterations of DNA methylation associated with
abnormalities of DNA methyltransferases in human cancers during transition
from a precancerous to a malignant state. Carcinogenesis 28, 2434–2442. doi:
10.1093/carcin/bgm206
Kanai, Y., Ushijima, S., Tsuda, H., Sakamoto, M., Sugimura, T., and Hirohashi,
S. (1996). Aberrant DNA methylation on chromosome 16 is an early event in
hepatocarcinogenesis. Jpn. J. Cancer Res. 87, 1210–1217. doi: 10.1111/j.1349-
7006.1996.tb03135.x
Kim, D. H., Saetrom, P., Snøve, O. Jr., and Rossi, J. J. (2008). MicroRNA-directed
transcriptional gene silencing in mammalian cells. Proc. Natl. Acad. Sci. U.S.A.
105, 16230–16235. doi: 10.1073/pnas.0808830105
Lister, R., O’Malley, R. C., Tonti-Filippini, J., Gregory, B. D., Berry, C. C., Millar, A.
H., et al. (2008). Highly integrated single-base resolution maps of the epigenome
in Arabidopsis. Cell 133, 523–536. doi: 10.1016/j.cell.2008.03.029
Lujambio, A., Ropero, S., Ballestar, E., Fraga, M. F., Cerrato, C., Setién, F.,
et al. (2007). Genetic unmasking of an epigenetically silenced microRNA in
human cancer cells. Cancer Res. 67, 1424–1429. doi: 10.1158/0008-5472.CAN-
06-4218
Miura, F., Enomoto, Y., Dairiki, R., and Ito, T. (2012). Ampliﬁcation-free whole-
genome bisulﬁte sequencing by post-bisulﬁte adaptor tagging. Nucleic Acids Res.
40, e136. doi: 10.1093/nar/gks454
Nakagawa, T., Kanai, Y., Ushijima, S., Kitamura, T., Kakizoe, T., and Hiro-
hashi, S. (2005). DNA hypermethylation on multiple CpG islands asso-
ciated with increased DNA methyltransferase DNMT1 protein expression
during multistage urothelial carcinogenesis. J. Urol. 173, 1767–1771. doi:
10.1097/01.ju.0000154632.11824.4d
Nishiyama, N., Arai, E., Chihara, Y., Fujimoto, H., Hosoda, F., Shibata, T., et al.
(2010). Genome-wide DNA methylation proﬁles in urothelial carcinomas and
urothelia at the precancerous stage. Cancer Sci. 101, 231–240. doi: 10.1111/j.1349-
7006.2009.01330.x
Peng, D. F., Kanai, Y., Sawada, M., Ushijima, S., Hiraoka, N., Kitazawa,
S., et al. (2006). DNA methylation of multiple tumor-related genes in asso-
ciation with overexpression of DNA methyltransferase 1 (DNMT1) during
multistage carcinogenesis of the pancreas. Carcinogenesis 27, 1160–1168. doi:
10.1093/carcin/bgi361
Saito, Y., Kanai, Y., Sakamoto, M., Saito, H., Ishii, H., and Hirohashi, S. (2002).
Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4,
associated with DNA hypomethylation on pericentromeric satellite regions dur-
ing human hepatocarcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 99, 10060–10065.
doi: 10.1073/pnas.152121799
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., and Coetzee. G.
A., et al. (2006). Speciﬁc activation of microRNA-127 with downregulation of
the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.
Cancer Cell 9, 435–443. doi: 10.1016/j.ccr.2006.04.020
Saito, Y., Saito, H., Liang, G., and Friedman, J. M. (2013). Epigenetic alterations and
microRNA misexpression in cancer and autoimmune diseases: a critical review.
Clin. Rev. Allergy Immunol. doi: 10.1007/s12016-013-8401-z [Epub ahead of
print].
Saito, Y., Suzuki, H., Tsugawa, H., Nakagawa, I., Matsuzaki, J., Kanai, Y., et al. (2009).
Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced
microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.
Oncogene 28, 2738–2744. doi: 10.1038/onc.2009.140
Sato, T., Arai, E., Kohno T., Takahashi, Y., Miyata, S., Tsuta, K., et al. (2014). Epige-
netic clustering of lung adenocarcinomas based on DNA methylation proﬁles in
adjacent lung tissue: its correlation with smoking history and chronic obstructive
pulmonary disease. Int. J. Cancer doi: 10.1002/ijc.28684
Sato, T., Arai, E., Kohno, T., Tsuta, K., Watanabe, S., Soejima, K., et al. (2013). DNA
methylation proﬁles at precancerous stages associated with recurrence of lung
adenocarcinoma. PLoS ONE 8:e59444. doi: 10.1371/journal.pone.0059444
Frontiers in Genetics | Epigenomics and Epigenetics February 2014 | Volume 5 | Article 24 | 6
Kanai and Arai Multilayer-omics analyses and IHEC
Yoshiura, K., Kanai, Y., Ochiai, A., Shimoyama, Y., Sugimura, T., and Hirohashi,
S. (1995). Silencing of the E-cadherin invasion-suppressor gene by CpG methy-
lation in human carcinomas. Proc. Natl. Acad. Sci. U.S.A. 92, 7416–7419. doi:
10.1073/pnas.92.16.7416
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 14 January 2014; accepted: 24 January 2014; published online: 14 February
2014.
Citation: Kanai Y and Arai E (2014) Multilayer-omics analyses of human cancers:
exploration of biomarkers and drug targets based on the activities of the International
Human Epigenome Consortium. Front. Genet. 5:24. doi: 10.3389/fgene.2014.00024
This article was submitted to Epigenomics and Epigenetics, a section of the journal
Frontiers in Genetics.
Copyright © 2014 Kanai and Arai. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org February 2014 | Volume 5 | Article 24 | 7
